CommercialCoverageLow impact
08.01.49b, Burosumab-twza (Crysvita®)
Independence Blue Cross·Endocrinology, Pediatrics, Nephrology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
The Burosumab-twza (Crysvita®) pharmacy policy has been reissued and will become effective May 28, 2025. This appears to be an updated policy for this rare disease medication used to treat certain phosphate wasting disorders, though specific changes are not detailed in the summary provided.
Action Required
By May 28, 2025: Billing team should review the full policy document at the provided URL to understand specific changes to Burosumab-twza (Crysvita®) coverage, prior authorization requirements, or billing procedures. Update any relevant protocols for this specialty medication if changes are identified.